novo glp-1 Ozempic's patent problem: how Nordisk lost control of a blockbuster drug. 💉 Demand for weight-loss drugs has exploded, turning Ozempic into a $40bn+ revenue engine for Novo Nordisk. But, despite Scoring 2 Million Prescriptions, Novo's

Colom C, Rull A, Sanchez-Quesada JL, Prez A (2021) Cardiovascular disease in type 1 diabetes mellitus: epidemiology and management of cardiovascular risk

A Comprehensive Approach to Weight Loss About Physician-Supervised Medical Weight Loss Physician-supervised medical weight loss is a comprehensive approach that combines scientifically backed treatments with healthy lifestyle counseling to achieve sustainable results

These agents are being studied across both first and second line, with subcutaneous, oral, and novel routes of administration (ROAs)

Semaglutide: Targets the GLP-1 pathway only Focuses on appetite regulation and fullness Tirzepatide: Targets both GLP-1 and GIP pathways May create a broader metabolic response Although this difference sounds technical, it can influence how patients respond to treatment

Cycling further minimizes accumulation

Our dedicated team is here to support your journey toward a healthier, more active lifestyle